Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLMC 2020 | The future role of MRD measurement in CLL

Jenifer Woyach, MD, The Ohio State University, Columbus, OH, discusses the current and future role of minimal residual disease (MRD) measurement in chronic lymphocytic leukemia (CLL). Dr/Prof Woyach highlights the approval of the ClonoSEQ sequencing method which has superior sensitivity to MRD in CLL patients compared with previous methods, and the potential of retrospective and prospective studies to determine whether CLL treatment duration could be based on MRD in the future. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consulting/advisory boards: Janssen, Pharmacyclics, Abbvie, AstraZeneca, Arqule